SCHEMBL33532001

SCHEMBL33532001

O=C(N1CCCC1c1cccc(Br)c1)C(F)(F)F

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 4/20 0.58
SCD5 Q86SK9 3/20 0.48
KMT2A Q03164 1/20 0.47
ROCK2 O75116 1/20 0.46
ALDH1A1 P00352 1/20 0.42
ESR1 P03372 2/20 0.42
ESR2 Q92731 2/20 0.42
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
PDE5A O76074 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40
DRD2 P14416 1/20 0.40
DRD1 P21728 1/20 0.40
DRD4 P21917 1/20 0.40
DRD5 P21918 1/20 0.40
DRD3 P35462 1/20 0.40
KDM1A O60341 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
SCD O00767 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22498217 0.83 SCD5 (0.51) RIPK1SCD5KMT2AROCK2ALDH1A1
SCHEMBL17513396 0.83 SCD5 (0.51) RIPK1SCD5KMT2AROCK2ALDH1A1
SCHEMBL1576663 0.83 RIPK1 (0.73) RIPK1SCD5ESR1ESR2HSP90AA1
SCHEMBL25319552 0.80 SCD5 (0.47) RIPK1SCD5KMT2AROCK2ALDH1A1
SCHEMBL26926756 0.80 USP30 (0.53) RIPK1SCD5KMT2AROCK2ALDH1A1
SCHEMBL22505052 0.80 USP30 (0.53) RIPK1SCD5KMT2AROCK2ALDH1A1
SCHEMBL3663950 0.80 USP30 (0.53) RIPK1SCD5KMT2AROCK2ALDH1A1
SCHEMBL29641537 0.80 USP30 (0.53) RIPK1SCD5KMT2AROCK2ALDH1A1
SCHEMBL28171621 0.79 RIPK1 (0.67) RIPK1SCD5ESR1ESR2HSP90AA1
SCHEMBL25965056 0.77 BTK (0.48) RIPK1SCD5KMT2AROCK2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092061-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LTD (GB) 2026-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092061-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION BCL9L, RBBP9, BRD9 RIPK1 1512/4885SCD5 4473/4885KMT2A 4018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.